

## **SUPPLEMENTARY MATERIALS**

**Title:** Global economic burden associated with chronic kidney disease: A pragmatic review of medical costs for the Inside CKD research programme

**Authors:** Vivekanand Jha,<sup>1,2</sup> Saeed M.G. Al-Ghamdi,<sup>3</sup> Guisen Li,<sup>4</sup> Mai-Szu Wu,<sup>5</sup> Panagiotis Stafylas,<sup>6</sup> Lise Retat,<sup>7</sup> Joshua Card-Gowers,<sup>7</sup> Salvatore Barone,<sup>8</sup> Claudia Cabrera,<sup>9</sup> Juan Jose Garcia Sanchez<sup>10</sup>

*(1) School of Public Health, Imperial College, London, United Kingdom, (2) Manipal Academy of Higher Education, Manipal, India, (3) Department of Medicine, College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, (4) Sichuan Provincial People's Hospital, Chengdu, China, (5) Division of Nephrology, Taipei Medical University, Taipei, Taiwan, (6) Medical Research & Innovation (HEALTHINK), Thessaloniki, Greece, (7) HealthLumen Limited, London, United Kingdom, (8) Global Medical Affairs AstraZeneca, Gaithersburg, Maryland, United States, (9) Global Medical Affairs, AstraZeneca, Gothenburg, Sweden, (10) Health Economic and Payer Evidence, AstraZeneca, Cambridge, United Kingdom*

**Corresponding author:** Juan Jose Garcia Sanchez

Email: [juanjose.garciasanchez@astrazeneca.com](mailto:juanjose.garciasanchez@astrazeneca.com)

## TABLES

**Table S1. Inside CKD Scientific Steering Committee**

Country/region	Expert	Affiliation
Australia	Prof. Steven Chadban	Royal Prince Alfred Hospital, Sydney, Australia
Belgium	Prof. Michel Jadoul	Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
Brazil	Prof. Marcelo Costa Batista	Hospital Israelita Albert Einstein, São Paulo, Brazil
Canada	Dr Navdeep Tangri	University of Manitoba, Winnipeg, Canada
China	Prof. Guisen Li	Sichuan Provincial People's Hospital, Chengdu, China
Colombia	Prof. José Javier Arango Álvarez	Universidad del Quindío, Quindío, Colombia
Denmark	Professor Christian Fynbo Christiansen	Aarhus University Hospital, Denmark
France	Prof. Jean-Michel Halimi	Service de Néphrologie-HTA, Dialyses, Transplantation Rénale, CHU Tours, Tours, France
Germany	Prof. Kai-Uwe Eckardt	Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany
Greece	Dr. Panagiotis Stafylas	Medical Research & Innovation (HealThink), Thessaloniki, Greece, and Laboratory of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
Hungary	Prof. Istvan Wittmann	President of Hungarian Diabetes Society and Hungarian College of nephrologists and Head of the Internal Medicine Department II. at University of Pécs.
India	Prof. Vivekanand Jha	George Institute for Global Health India, New Delhi, India
Israel	Prof. Avraham Karasik	Maccabi Institute for Research and Innovation, Tel-Aviv, Israel
Israel	Prof. Gil Chernin	Kaplan Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
Italy	Prof. Francesco Saverio Mennini	CEIS-EEHTA, Faculty of Economics, University of Rome Tor Vergata, Rome, Italy
Italy	Prof. Luca De Nicola	Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy
Japan	Prof. Eiichiro Kanda	Kawasaki Medical University, Okayama, Japan
Mexico	Prof. José Ricardo Correa-Rotter	Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City, Mexico
Netherlands	Dr Chris Hagen	Meander Medical Centre
Philippines, Singapore, and Thailand	Assoc. Prof. Jason Choo Chon Jun	Singapore General Hospital, Singapore
Poland	Prof. Michał Nowicki	Warsaw University of Technology
Romania	Prof. Dr. Ismail Gener	Fundeni Institute
Saudi Arabia	Prof. Saeed M. G. Al-Ghamdi	King Abdulaziz University Hospital and King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia
South Korea	Prof. Kook-Hwan Oh	Seoul National University College of Medicine, Seoul, South Korea
Spain	Prof. Juan Francisco Navarro-González	Research Unit and Nephrology Service, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
Sweden	Prof. Johan Ärnlöv	Department of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institute, Stockholm, Sweden
Taiwan	Prof. Mai-Szu Wu	Division of Nephrology, Taipei Medical University, Taipei, Taiwan
Turkey	Prof. Mustafa ARICI	Hacettepe University Faculty of Medicine, Department of Nephrology, Ankara, Turkey

<b>Country/region</b>	<b>Expert</b>	<b>Affiliation</b>
United Arab Emirates	Prof. Stephen Holt	SEHA Kidney Care, Abu Dhabi, UAE
United Kingdom	Dr Albert Power	North Bristol NHS Trust, Bristol, UK
United States of America	Prof. Glenn Chertow	Stanford University School of Medicine, California, USA
United States of America	Prof. Jay Wish	Indiana University School of Medicine, Indianapolis, USA

**Table S2. Implied purchasing power parity conversion rates (national currency per international dollar) per country/region<sup>1</sup>**

Country/region	Currency	Conversion rates
Australia	AUS (\$)	1.47
Belgium	EUR (€)	0.75
Brazil	BRL (R\$)	2.62
Canada	CAD (\$)	1.25
China	CNY (¥)	4.15
Colombia	COP (\$)	1,374.82
Denmark	DKK (kr.)	6.59
France	EUR (€)	0.73
Germany	EUR (€)	0.73
Greece	EUR (€)	0.51
Hungary	HUF (Ft)	150.40
India	INR (₹)	22.59
Israel	ILS (₪)	3.58
Italy	EUR (€)	0.65
Japan	JPY (¥)	96.14
Mexico	MXN (\$)	9.65
Netherlands	EUR (€)	0.78
Philippines	PHP (₱)	19.33
Poland	PLN (zł)	1.80
Romania	RON (lei)	1.82
Saudi Arabia	SAR (ر.س.)	1.76
Singapore	SGD (S\$)	0.81
South Korea	KRW (₩)	819.75
Spain	EUR (€)	0.60
Sweden	SEK (kr)	8.62
Taiwan	NTD (\$)	14.96
Thailand	THB (฿)	11.86
Turkey	TRY (₺)	2.53
UAE	AED (إ.د.)	2.12
UK	GBP (£)	0.68
USA	USD (\$)	1.00

**Table S3. Annual per patient chronic kidney disease management costs by GFR stage (local currency, 2022 values)**

Country/region	Currency	Stage G3a		Stage G3b		Stage G4		Stage G5	
		Source year	Inflated cost	Source year	Inflated cost	Source year	Inflated cost	Source year	Inflated cost
Australia	AUS (\$)	2012	4,152 <sup>[2]</sup>	2012	4,152 <sup>[2]</sup>	2012	17,310 <sup>[2]</sup>	2012	17,310 <sup>[2]</sup>
Belgium	EUR (€)	2021	2,727 <sup>[3]</sup>	2021	2,814 <sup>[3]</sup>	2021	4,960 <sup>[3]</sup>	2021	10,056 <sup>[3]</sup>
Brazil	BRL (R\$)	2021	3,296 <sup>[4]</sup>	2021	3,714 <sup>[4]</sup>	2021	4,850 <sup>[4]</sup>	2021	8,019 <sup>[4]</sup>
Canada	CAD (\$)	2017	4,600 <sup>[5]</sup>	2017	6,474 <sup>[5]</sup>	2017	10,378 <sup>[5]</sup>	2017	25,650 <sup>[5]</sup>
China	CNY (¥)	2018	11,091 <sup>[6]</sup>	2018	11,091 <sup>[6]</sup>	2018	31,195 <sup>[6]</sup>	2018	35,039 <sup>[6]</sup>
Colombia	COP (\$)	2020	1,604,090 <sup>[7]</sup>	2020	1,604,090 <sup>[7]</sup>	2020	2,195,316 <sup>[7]</sup>	2020	2,576,458 <sup>[7]</sup>
Denmark	DKK (kr.)	2014	8,294 <sup>[4]</sup>	2014	9,345 <sup>[4]</sup>	2014	12,204 <sup>[4]</sup>	2014	20,179 <sup>[4]</sup>
France	EUR (€)	2021	2,715 <sup>[3]</sup>	2021	2,801 <sup>[3]</sup>	2021	4,937 <sup>[3]</sup>	2021	10,011 <sup>[3]</sup>
Germany	EUR (€)	2014	4,285 <sup>[8]</sup>	2014	4,285 <sup>[8]</sup>	2014	4,976 <sup>[8]</sup>	2014	12,757 <sup>[8]</sup>
Greece	EUR (€)	2021	402 <sup>[4]</sup>	2021	402 <sup>[4]</sup>	2021	1,262 <sup>[4]</sup>	2021	2,105 <sup>[4]</sup>
Hungary	HUF (Ft)	2022	183,184 <sup>[9]</sup>	2022	211,511 <sup>[9]</sup>	2022	233,720 <sup>[9]</sup>	2022	353,545 <sup>[9]</sup>
India	INR (₹)	2016	43,373 <sup>[10]</sup>	2016	43,373 <sup>[10]</sup>	2016	39,357 <sup>[10]</sup>	2016	103,849 <sup>[10]</sup>
Israel	ILS (₪)	2014	21,167 <sup>[8]</sup>	2014	21,167 <sup>[8]</sup>	2014	24,576 <sup>[8]</sup>	2014	63,013 <sup>[8]</sup>
Italy	EUR (€)	2012	1,553 <sup>[11]</sup>	2012	2,256 <sup>[11]</sup>	2012	3,774 <sup>[11]</sup>	2012	4,632 <sup>[11]</sup>
Japan	JPY (¥)	2018	257,119 <sup>[6]</sup>	2018	257,119 <sup>[6]</sup>	2018	723,210 <sup>[6]</sup>	2018	812,331 <sup>[6]</sup>
Mexico	MXN (\$)	2017	14,135 <sup>[12]</sup>	2017	14,135 <sup>[12]</sup>	2017	15,269 <sup>[12]</sup>	2017	113,498 <sup>[12]</sup>
Netherlands	EUR (€)	2021	976 <sup>[4]</sup>	2021	1,099 <sup>[4]</sup>	2021	1,436 <sup>[4]</sup>	2021	2,374 <sup>[4]</sup>
Philippines	PHP (₱)	2019	8,092 <sup>[13]</sup>	2019	10,348 <sup>[13]</sup>	2019	16,034 <sup>[13]</sup>	2016	88,853 <sup>[10]</sup>
Poland	PLN (zł)	2021	68 <sup>[14]</sup>	2021	274 <sup>[14]</sup>	2021	548 <sup>[14]</sup>	2021	617 <sup>[14]</sup>
Romania	RON (lei)	2019	3,162 <sup>[15]</sup>	2019	3,651 <sup>[15]</sup>	2019	4,035 <sup>[15]</sup>	2019	6,103 <sup>[15]</sup>
Saudi Arabia	SAR (ر.س.)	2014	10,397 <sup>[8]</sup>	2014	10,397 <sup>[8]</sup>	2014	12,072 <sup>[8]</sup>	2014	30,952 <sup>[8]</sup>
Singapore	SGD (S\$)	2015	4,508 <sup>[16]</sup>	2015	4,638 <sup>[16]</sup>	2015	5,338 <sup>[16]</sup>	2013	6,553 <sup>[17]</sup>
South Korea	KRW (₩)	2017	1,347,781 <sup>[18]</sup>	2017	1,347,781 <sup>[18]</sup>	2017	2,194,716 <sup>[18]</sup>	2017	8,985,060 <sup>[18]</sup>
Spain	EUR (€)	2005	1,225 <sup>[19]</sup>	2011	3,836 <sup>[20]</sup>	2011	3,836 <sup>[20]</sup>	2011	5,000 <sup>[20]</sup>
Sweden	SEK (kr)	2021	28,611 <sup>[11,21]</sup>	2021	46,185 <sup>[11,21]</sup>	2021	69,887 <sup>[11,21]</sup>	2021	102,363 <sup>[11,21]</sup>
Taiwan	NTD (\$)	2018	40,011 <sup>[6]</sup>	2018	40,011 <sup>[6]</sup>	2018	112,541 <sup>[6]</sup>	2018	126,410 <sup>[6]</sup>
Thailand	THB (฿)	2017	4,966 <sup>[13]</sup>	2017	6,350 <sup>[13]</sup>	2017	9,839 <sup>[13]</sup>	2016	54,525 <sup>[10]</sup>
Turkey	TRY (₺)	2022	4,294 <sup>[a]</sup>	2022	4,294 <sup>[a]</sup>	2022	11,731 <sup>[a]</sup>	2022	13,001 <sup>[a]</sup>
UAE	AED (د.ا.)	2012	5,062 <sup>[11]</sup>	2012	7,355 <sup>[11]</sup>	2012	12,300 <sup>[11]</sup>	2012	15,099 <sup>[11]</sup>
UK	GBP (£)	2021	851 <sup>[4]</sup>	2021	959 <sup>[4]</sup>	2021	1,252 <sup>[4]</sup>	2021	2,071 <sup>[4]</sup>
USA (commercial)	USD (\$)	2013	13,124 <sup>[22]</sup>	2013	15,514 <sup>[22]</sup>	2013	18,270 <sup>[22]</sup>	2013	18,270 <sup>[22]</sup>
USA (Medicare)		2013	11,908 <sup>[22]</sup>	2013	13,101 <sup>[22]</sup>	2013	15,179 <sup>[22]</sup>	2013	15,179 <sup>[22]</sup>

<sup>a</sup>Expert opinion

**Table S4. Annual per patient kidney replacement therapy costs by treatment modality (local currency, 2022 values)**

Country/region	Currency	Haemodialysis		Peritoneal dialysis		Kidney transplant (year 1)		Kidney transplant (year 2+)	
		Source year	Inflated cost	Source year	Inflated cost	Source year	Inflated cost	Source year	Inflated cost
Australia	AUS (\$)	2009	103,356 <sup>[23]</sup>	2009	69,424 <sup>[23]</sup>	2009	127,288 <sup>[23]</sup>	2004	17,197 <sup>[24]</sup>
Belgium	EUR (€)	2013	77,428 <sup>[3]</sup>	2021	56,444 <sup>[3]</sup>	2007	47,186 <sup>[3]</sup>	2007	7,717 <sup>[3]</sup>
Brazil	BRL (R\$)	2018	39,237 <sup>[25]</sup>	2018	44,420 <sup>[25]</sup>	2013	137,357 <sup>[26]</sup>	2013	14,846 <sup>[26]</sup>
Canada	CAD (\$)	2016	82,722 <sup>[27]</sup>	2016	49,802 <sup>[27]</sup>	2008	125,593 <sup>[28]</sup>	2008	24,028 <sup>[28]</sup>
China	CNY (¥)	2015	101,629 <sup>[29]</sup>	2015	85,463 <sup>[29]</sup>	2010	96,709 <sup>[30]</sup>	2020	60,683 <sup>[31]</sup>
Colombia	COP (\$)	2020	34,635,252 <sup>[7]</sup>	2020	34,635,252 <sup>[7]</sup>	2020	66,084,138 <sup>[32]</sup>	2017	8,383,442 <sup>[33]</sup>
Denmark	DKK (kr.)	2009	446,789 <sup>[34]</sup>	2009	287,167 <sup>[34]</sup>	2014	387,333 <sup>[35]</sup>	2014	92,860 <sup>[35]</sup>
France	EUR (€)	2012	98,489 <sup>[36]</sup>	2012	71,637 <sup>[36]</sup>	2012	96,114 <sup>[36]</sup>	2012	22,394 <sup>[36]</sup>
Germany	EUR (€)	2006	70,773 <sup>[37]</sup>	2006	70,773 <sup>[37]</sup>	2006	114,903 <sup>[38]</sup>	2006	11,951 <sup>[38]</sup>
Greece	EUR (€)	2017	39,034 <sup>[39]</sup>	2017	51,758 <sup>[39]</sup>	2008	32,966 <sup>[40]</sup>	2008	5,183 <sup>[40]</sup>
Hungary	HUF (Ft)	2022	4,500,000 <sup>[9]</sup>	2022	3,028,443 <sup>[41]</sup>	2022	6,200,000 <sup>[9]</sup>	2022	2,812,369 <sup>[42]</sup>
India	INR (₹)	2015	117,074 <sup>[43]</sup>	2015	117,074 <sup>[43]</sup>	2011	576,714 <sup>[44]</sup>	2009	179,999 <sup>[45]</sup>
Israel	ILS (₪)	2017	296,574 <sup>[46]</sup>	2017	250,716 <sup>[46]</sup>	2006	567,540 <sup>[38]</sup>	2006	59,031 <sup>[38]</sup>
Italy	EUR (€)	2013	35,700 <sup>[47]</sup>	2013	35,523 <sup>[47]</sup>	2011	73,788 <sup>[48]</sup>	2011	11,197 <sup>[49]</sup>
Japan	JPY (¥)	2022	4,800,000 <sup>[50]</sup>	2022	3,600,000 <sup>[50]</sup>	2010	3,913,242 <sup>[51]</sup>	2011	1,000,932 <sup>[52]</sup>
Mexico	MXN (\$)	2017	145,686 <sup>[53]</sup>	2017	119,659 <sup>[53]</sup>	2017	484,671 <sup>[54]</sup>	2017	58,814 <sup>[54]</sup>
Netherlands	EUR (€)	2014	105,862 <sup>[55]</sup>	2014	97,223 <sup>[55]</sup>	2014	97,563 <sup>[55]</sup>	2014	21,997 <sup>[55]</sup>
Philippines	PHP (₱)	2017	454,073 <sup>[56]</sup>	2016	309,281 <sup>[57]</sup>	2020	1,476,151 <sup>[58]</sup>	2016	458,195 <sup>[59, b]</sup>
Poland	PLN (zł)	2021	70,249 <sup>[14]</sup>	2021	90,068 <sup>[14]</sup>	2021	67,297 <sup>[14]</sup>	2014	17,311 <sup>[60]</sup>
Romania	RON (lei)	2021	95,576 <sup>[15]</sup>	2019	65,011 <sup>[15]</sup>	2019	198,067 <sup>[15]</sup>	2019	6,103 <sup>[15, a]</sup>
Saudi Arabia	SAR (ر.س.)	2018	64,243 <sup>[61]</sup>	2018	75,620 <sup>[61]</sup>	2020	68,187 <sup>[62]</sup>	2010	20,715 <sup>[63]</sup>
Singapore	SGD (S\$)	2021	31,653 <sup>[b]</sup>	2021	21,914 <sup>[b]</sup>	2022	95,000 <sup>[b]</sup>	2021	12,682 <sup>[b]</sup>
South Korea	KRW (₩)	2017	38,639,047 <sup>[18]</sup>	2017	28,856,366 <sup>[18]</sup>	2017	76,931,225 <sup>[18]</sup>	2017	39,992,979 <sup>[18]</sup>
Spain	EUR (€)	2011	52,134 <sup>[20]</sup>	2011	52,134 <sup>[20]</sup>	2017	24,119 <sup>[62]</sup>	2010	7,066 <sup>[63]</sup>
Sweden	SEK (kr)	2021	961,726 <sup>[21]</sup>	2021	643,873 <sup>[21]</sup>	2021	641,207 <sup>[64]</sup>	2021	130,807 <sup>[64]</sup>
Taiwan	NTD (\$)	2017	403,951 <sup>[65]</sup>	2013	323,162 <sup>[66]</sup>	2019	175,151 <sup>[67]</sup>	2018	126,410 <sup>[6]</sup>
Thailand	THB (฿)	2014	286,810 <sup>[68]</sup>	2020	75,381 <sup>[69]</sup>	2014	1,013,549 <sup>[70]</sup>	2014	468,919 <sup>[70]</sup>
Turkey	TRY (₺)	2021	60,556 <sup>[71]</sup>	2021	149,666 <sup>[71]</sup>	2021	79,159 <sup>[71]</sup>	2022	21,396 <sup>[b]</sup>
UAE	AED (د.ا.)	2022	150,000 <sup>[b]</sup>	2022	120,000 <sup>[b]</sup>	2011	240,520 <sup>[48]</sup>	2011	36,499 <sup>[49]</sup>
UK	GBP (£)	2018	24,689 <sup>[72]</sup>	2018	29,061 <sup>[72]</sup>	2019	28,775 <sup>[73]</sup>	2009	6,369 <sup>[45]</sup>
USA	USD (\$)	2017	103,072 <sup>[74]</sup>	2017	87,761 <sup>[74]</sup>	2015	120,203 <sup>[75]</sup>	2012	49,603 <sup>[76]</sup>

<sup>a</sup>Stage 5 proxy; <sup>b</sup>Expert opinion

**Table S5. Annual per patient CKD associated complication costs (local currency, 2022 values)**

Country/region	Currency	Myocardial infarction		Heart failure		Stroke		Acute kidney injury	
		Source year	Inflated cost	Source year	Inflated cost	Source year	Inflated cost	Source year	Inflated cost
Australia	AUS (\$)	2005	31,380 <sup>[77]</sup>	2017	19,587 <sup>[78]</sup>	2020	1,914 <sup>[79]</sup>	2022	11,818 <sup>[80]</sup>
Belgium	EUR (€)	2011	17,636 <sup>[3]</sup>	2021	13,903 <sup>[3]</sup>	2021	15,941 <sup>[3]</sup>	2021	28,191 <sup>[3]</sup>
Brazil	BRL (R\$)	2015	72,672 <sup>[81]</sup>	2015	7,679 <sup>[81]</sup>	2018	1,818 <sup>[82]</sup>	2018	2,540 <sup>[83]</sup>
Canada	CAD (\$)	2013	15,747 <sup>[84]</sup>	2014	13,007 <sup>[85]</sup>	2009	13,075 <sup>[86]</sup>	2015	12,497 <sup>[87]</sup>
China	CNY (¥)	2012	28,774 <sup>[88]</sup>	2014	33,805 <sup>[89]</sup>	2016	12,300 <sup>[90]</sup>	2013	25,965 <sup>[91]</sup>
Colombia	COP (\$)	2016	123,804,225 <sup>[92]</sup>	2017	6,921,038 <sup>[53]</sup>	2017	13,797,320 <sup>[53]</sup>	2022	10,736,798 <sup>[93]</sup>
Denmark	DKK (kr.)	2014	144,859 <sup>[94]</sup>	2016	35,487 <sup>[95]</sup>	2009	73,575 <sup>[96]</sup>	2018	33,232 <sup>[97,98]</sup>
France	EUR (€)	2016	8,663 <sup>[99]</sup>	2017	8,461 <sup>[100]</sup>	2007	19,620 <sup>[101]</sup>	2015	17,910 <sup>[102]</sup>
Germany	EUR (€)	2014	15,942 <sup>[94]</sup>	2014	3,936 <sup>[94]</sup>	2014	15,012 <sup>[94]</sup>	2022	2,006 <sup>[103]</sup>
Greece	EUR (€)	2012	5,227 <sup>[104]</sup>	2016	4,403 <sup>[105]</sup>	2012	4,370 <sup>[104]</sup>	2022	1,091 <sup>[106]</sup>
Hungary	HUF (Ft)	2019	344,975 <sup>[15]</sup>	2020	23,731 <sup>[9]</sup>	2017	471,665 <sup>[107]</sup>	2022	363,068 <sup>[108]</sup>
India	INR (₹)	2016	85,355 <sup>[109, a]</sup>	2016	85,355 <sup>[109]</sup>	2011	183,290 <sup>[110]</sup>	2012	45,818 <sup>[111]</sup>
Israel	ILS (₪)	2014	78,740 <sup>[94]</sup>	2014	19,443 <sup>[94]</sup>	2004	75,525 <sup>[94]</sup>	2022	17,905 <sup>[112]</sup>
Italy	EUR (€)	2004	15,567 <sup>[113]</sup>	2013	13,115 <sup>[114]</sup>	2007	14,172 <sup>[115]</sup>	2022	3,784 <sup>[116]</sup>
Japan	JPY (¥)	2014	2,263,397 <sup>[117]</sup>	2015	871,198 <sup>[118]</sup>	2022	949,876 <sup>[52]</sup>	2022	21,045 <sup>[119]</sup>
Mexico	MXN (\$)	2016	868,544 <sup>[92]</sup>	2017	96,795 <sup>[53]</sup>	2017	48,554 <sup>[53]</sup>	2022	10,761 <sup>[120]</sup>
Netherlands	EUR (€)	2020	3,212 <sup>[121]</sup>	2014	6,910 <sup>[122]</sup>	2000	3,623 <sup>[123]</sup>	2022	5,730 <sup>[124]</sup>
Philippines	PHP (₱)	2012	38,490 <sup>[125]</sup>	2016	87,967 <sup>[109]</sup>	2013	76,946 <sup>[126]</sup>	2022	19,300 <sup>[127]</sup>
Poland	PLN (zł)	2012	18,416 <sup>[104]</sup>	2016	15,513 <sup>[105]</sup>	2014	15,416 <sup>[60]</sup>	2022	4,664 <sup>[108]</sup>
Romania	RON (lei)	2019	5,505 <sup>[15]</sup>	2019	5,401 <sup>[128]</sup>	2017	5,023 <sup>[107]</sup>	2022	10,362 <sup>[15]</sup>
Saudi Arabia	SAR (ر.س.)	2007	39,705 <sup>[113]</sup>	2020	20,598 <sup>[129]</sup>	2020	26,697 <sup>[130]</sup>	2019	11,062 <sup>[131]</sup>
Singapore	SGD (S\$)	2004	15,021 <sup>[132]</sup>	2015	7,227 <sup>[129]</sup>	2012	13,532 <sup>[133]</sup>	2021	2,793 <sup>[134]</sup>
South Korea	KRW (₩)	2012	12,615,808 <sup>[135]</sup>	2017	314,695 <sup>[136]</sup>	2015	5,358,435 <sup>[137]</sup>	2021	2,837,170 <sup>[134]</sup>
Spain	EUR (€)	2004	12,189 <sup>[113]</sup>	2015	7,404 <sup>[129]</sup>	2012	9,200 <sup>[130]</sup>	2021	4,393 <sup>[138,139]</sup>
Sweden	SEK (kr)	2022	49,274 <sup>[140]</sup>	2022	80,529 <sup>[140]</sup>	2022	105,696 <sup>[140]</sup>	2022	39,392 <sup>[141]</sup>
Taiwan	NTD (\$)	2019	15,042 <sup>[142]</sup>	2019	10,877 <sup>[142]</sup>	2019	34,564 <sup>[142]</sup>	2022	4,605 <sup>[143]</sup>
Thailand	THB (฿)	2012	24,843 <sup>[125]</sup>	2016	44,815 <sup>[109]</sup>	2014	26,086 <sup>[70]</sup>	2017	17,866 <sup>[144]</sup>
Turkey	TRY (₺)	2021	3,426 <sup>[b]</sup>	2021	5,746 <sup>[145]</sup>	2022	23,751 <sup>[b]</sup>	2022	3,867 <sup>[106]</sup>
UAE	AED (د.ا.)	2004	50,741 <sup>[113]</sup>	2013	42,748 <sup>[114]</sup>	2021	10,183 <sup>[146]</sup>	2019	13,345 <sup>[131]</sup>
UK	GBP (£)	2014	6,027 <sup>[122]</sup>	2000	3,160 <sup>[147]</sup>	2020	2,802 <sup>[121]</sup>	2009	2,494 <sup>[148]</sup>
USA	USD (\$)	2010	13,928 <sup>[149]</sup>	2017	24,930 <sup>[74]</sup>	2010	23,295 <sup>[149]</sup>	2014	8,684 <sup>[150]</sup>

<sup>a</sup>Heart failure proxy; <sup>b</sup>Expert opinion

## REFERENCES

1. International Monetary Fund. World Economic Outlook Database. 2022. Available at: <https://www.imf.org/en/Publications/WEO/weo-database/2022/October> [Accessed 01/11/2022].
2. Wyld ML, Lee CM, Zhuo X, et al. Cost to government and society of chronic kidney disease stage 1-5: a national cohort study. *Intern Med J.* 2015;45(7):741-7.
3. IQVIA. Hospital disease database analysis. [Internal analysis - data on file].
4. AstraZeneca. Analysis of Clinical Practice Research Datalink (CPRD) (4/5/2021, from the DAPA-CKD).
5. Manns B, Hemmelgarn B, Tonelli M, et al. The Cost of Care for People With Chronic Kidney Disease. *Can J Kidney Health Dis.* 2019;6:2054358119835521.
6. Okubo R, Kondo M, Hoshi SL, et al. Cost-Effectiveness of Behavior Modification Intervention for Patients With Chronic Kidney Disease in the FROM-J Study. *J Ren Nutr.* 2021;31(5):484-93.
7. Analysis from health centres and information from focus groups (data on file).
8. Gandjour A, Armsen W, Wehmeyer W, et al. Costs of patients with chronic kidney disease in Germany. *PLoS One.* 2020;15(4):e0231375.
9. Analysis of Hungarian NHIFA database (data on file). 2022.
10. Ahlawat R, Tiwari P, D'Cruz S. Direct Cost for Treating Chronic Kidney Disease at an Outpatient Setting of a Tertiary Hospital: Evidence from a Cross-Sectional Study. *Value Health Reg Issues.* 2017;12:36-40.
11. Jommi C, Armeni P, Battista M, et al. The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study. *Pharmacoecon Open.* 2018;2(4):459-67.
12. Villarreal-Ríos E, et al.,. Cost per stage of comprehensive care of type 2 diabetic patients with chronic kidney disease. *Physis: Revista de Saude Coletiva.* 2017;27: 1125-1146.
13. Songsermlosakul S, Permsuwan U, Singhan W. Treatment Costs for Patients with Chronic Kidney Disease Who Received Multidisciplinary Care in a District Hospital in Thailand. *Clinicoecon Outcomes Res.* 2020;12(223-231).
14. AEK Forxiga. Dapagliflozin (Forxiga) in the treatment of chronic kidney disease: Economic Analysis. 2021. Available at: [https://bipold.aotm.gov.pl/assets/files/zlecenia\\_mz/2021/181/AW/181\\_OT.4230.22.2021\\_F orxiga\\_AE.pdf](https://bipold.aotm.gov.pl/assets/files/zlecenia_mz/2021/181/AW/181_OT.4230.22.2021_F orxiga_AE.pdf) [Accessed 01/07/2022].
15. Analysis from national inpatient claims database (data on file).
16. Low S, Lim SC, Zhang X, et al. Medical costs associated with chronic kidney disease progression in an Asian population with type 2 diabetes mellitus. *Nephrology.* 2019;24(5):534-41.
17. Lim CC, Chee ML, Cheng CY, et al. Simplified end stage renal failure risk prediction model for the low-risk general population with chronic kidney disease. *PLoS One.* 2019;14(2):e0212590.
18. Kim SH, Jo MW, Go DS, et al. Economic burden of chronic kidney disease in Korea using national sample cohort. *Journal of Nephrology.* 2017;30:787-93.
19. Pons R, Torregrosa E, Hernández-Jaras J, et al. [Estimation of the cost in the pharmacologic treatment of chronic renal failure]. *Nefrología.* 2006;26(3):358-64.
20. Lorenzo-Sellares V, Pedrosa MI, Santana-Expósito B, et al. Cost analysis and sociocultural profile of kidney patients. Impact of the treatment method. *Nefrología.* 2014;34(4):458-68.
21. Eriksson JK, Neovius M, Jacobson SH, et al. Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden. *BMJ Open.* 2016;6(10):e012062.
22. Golestaneh L, Alvarez PJ, Reaven NL, et al. All-cause costs increase exponentially with increased chronic kidney disease stage. *Am J Manag Care.* 2017;23(10 Suppl):S163-S72.
23. Cass A, White S, Snelling P, et al. The economic impact of end-stage kidney disease in Australia: projections to 2020. 2010. Available at: <https://www.georgeinstitute.org/publications/the->



- economic-impact-of-end-stage-kidney-disease-in-australia-projections-to-2020 [Accessed 01/07/2022].
24. Howard K, White S, Salkeld G, et al. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis. *Value Health*. 2010;13(2):196-208.
  25. Sesso R, Lugon JR. Global Dialysis Perspective: Brazil. *Kidney360*. 2020;1(3):216-9.
  26. Brand S, Caulliraux H, Araujo C, et al. Uma comparação dos custos do transplante renal em relação às diálises no Brasil. *Cadernos de Saúde Pública*. 2016;32.
  27. Beaudry A, Ferguson TW, Rigatto C, et al. Cost of Dialysis Therapy by Modality in Manitoba. *Clin J Am Soc Nephrol*. 2018;13(8):1179-203.
  28. Barnieh L, Manns BJ, Klarenbach S, et al. A description of the costs of living and standard criteria deceased donor kidney transplantation. *Am J Transplant*. 2011;11(3):478-88.
  29. Wang F, Yang C, Long J, et al. Executive summary for the 2015 Annual Data Report of the China Kidney Disease Network (CK-NET). *Kidney Int*. 2019;95(3):501-5.
  30. Zhao W, Zhang L, Han S, et al. Cost analysis of living donor kidney transplantation in China: a single-center experience. *Ann Transplant*. 2012;17(2):5-10.
  31. Zhang L, Zhao MH, Zuo L, et al. China Kidney Disease Network (CK-NET) 2016 Annual Data Report. *Kidney Int Suppl (2011)*. 2020;10(2):e97-e185.
  32. Sarmiento-Bejarano H, Ramírez C, Carrasquilla-Sotomayor M, et al. Carga económica de la enfermedad renal crónica en Colombia, 2015-2016. *Salud Uninorte*. 2019;35:2019.
  33. Sanchez A, Cruz-Santiago J, Mariño-Rojas Fabiola B, et al. Carga de la enfermedad: insuficiencia renal, diálisis-hemodiálisis y trasplante renal en México. *Costo de la enfermedad. Revista Mexicana de Trasplantes*. 2020;9:15-25.
  34. Olsen J, Bonnevie B, Palmhøj Nielsen C, et al. Economic consequences of an increased number of patients on outgoing dialysis. *Scandinavian journal of urology and nephrology*. 2010;44:452-8.
  35. Jensen CE, Sørensen P, Petersen KD. In Denmark kidney transplantation is more cost-effective than dialysis. *Dan Med J*. 2014;61(3):A4796.
  36. Haute Autorite de Sante (HAS). Évaluation médico-économique des stratégies de prise en charge de l'insuffisance rénale chronique terminale en France. 2012. Available at: [https://www.has-sante.fr/upload/docs/application/pdf/2012-09/argu\\_irct\\_volet\\_greffe\\_vf.pdf](https://www.has-sante.fr/upload/docs/application/pdf/2012-09/argu_irct_volet_greffe_vf.pdf) [Accessed 01/11/2022].
  37. Icks A, Haastert B, Gandjour A, et al. Costs of dialysis--a regional population-based analysis. *Nephrol Dial Transplant*. 2010;25(5):1647-52.
  38. Kleophas W, Reichel H. International study of health care organization and financing: development of renal replacement therapy in Germany. *Int J Health Care Finance Econ*. 2007;7(2-3):185-200.
  39. Koukou MG, Smyrniotis VE, Arkadopoulos NF, et al. PD vs HD in Post-Economic Crisis Greece- Differences in Patient Characteristics and Estimation of Therapy Cost. *Perit Dial Int*. 2017;37(5):568-73.
  40. Kontodimopoulos N, Niakas D. An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy. *Health Policy*. 2008;86(1):85-96.
  41. Nemzeti Egészségbiztosítási Alapkezelő (NEAK). Honlapra gyógyító megelozo ellatas adatok 2008-2022. 2022. Available at: [https://neak.gov.hu/pfile/file?path=/letoltheto/altfin\\_dok/altfin\\_virt\\_dok2/publikus\\_adatok\\_gyme/alapdiajak\\_telj\\_adatok/A\\_gyogyito-megelozo\\_ellatasokra\\_vonatkozo\\_kozerdeku\\_adatok&inline=true](https://neak.gov.hu/pfile/file?path=/letoltheto/altfin_dok/altfin_virt_dok2/publikus_adatok_gyme/alapdiajak_telj_adatok/A_gyogyito-megelozo_ellatasokra_vonatkozo_kozerdeku_adatok&inline=true) [Accessed 01/02/2022].
  42. State Audit Office of Hungary. 2012.
  43. Kulkarni MJ, Jamale T, Hase NK, et al. A cross-sectional study of dialysis practice-patterns in patients with chronic kidney disease on maintenance hemodialysis. *Saudi J Kidney Dis Transpl*. 2015;26(5):1050-6.

44. Ramachandran R, Jha V. Kidney transplantation is associated with catastrophic out of pocket expenditure in India. *PLoS One*. 2013;8(7):e67812.
45. NHS Digital. Schedule 2 – The Services. 2017. Available at: <https://www.england.nhs.uk/wp-content/uploads/2017/05/service-spec-adult-kidney-transplant-service.pdf> [Accessed 01/07/2022].
46. Häckl D, Kossack N, Schoenfelder T. [Prevalence, Costs of Medical Treatment and Modalities of Dialysis-dependent Chronic Renal Failure in Germany: Comparison of Dialysis Care of Nursing Home Residents and in Outpatient Units]. *Gesundheitswesen*. 2021;83(10):818-28.
47. Vaccaro CM, Sopranzi F. A comparison between the costs of dialysis treatments in Marche Region, Italy: Macerata and Tolentino hospitals. *Ann Ist Super Sanita*. 2017;53(4):344-9.
48. Roggeri DP, Roggeri A, Zocchetti C, et al. Real-world data on healthcare resource consumption and costs before and after kidney transplantation. *Clin Transplant*. 2019;33(10):e13728.
49. Cavallo MC, Sepe V, Conte F, et al. Cost-effectiveness of kidney transplantation from DCD in Italy. *Transplantation Proceedings*. 2014;46(10):3289-96.
50. All Kidney Association - Japan Kidney Disease Council. Cost of dialysis treatment. 2022. Available at: <https://www.zjk.or.jp/kidney-disease/expense/dialysis/> [Accessed 01/10/2022].
51. Kitazawa T, Matsumoto K, Fujita S, et al. Cost Analysis of Transplantation in Japan, Performed With the Use of the National Database. *Transplant Proc*. 2017;49(1):4-9.
52. Kondo M, Yamagata K, Hoshi SL, et al. Cost-effectiveness of chronic kidney disease mass screening test in Japan. *Clinical and Experimental Nephrology*. 2012;16(2):279-91.
53. Arroyave-Loaiza MG, Siqueff-Jose JA, Amador-Vazquez L, et al. Grupos Relacionados con la Atención Ambulatoria de las Enfermedades Endocrinas, Nutricionales y Metabólicas (EGRAA). [Grupos Relacionados con la Atención Ambulatoria de las Enfermedades Endocrinas, Nutricionales y Metabólicas (EGRAA)]. Instituto Mexicano del Seguro Social; 2019.
54. Sánchez-Cedillo A, et al.,. Burden of disease: kidney failure, dialysis-hemodialysis, and kidney transplantation in Mexico. *Cost of illness. Rev Mex Trasl.* 2020; 9: 15-25.
55. Mohnen SM, van Oosten MJM, Los J, et al. Healthcare costs of patients on different renal replacement modalities - Analysis of Dutch health insurance claims data. *PLoS One*. 2019;14(8):e0220800.
56. Health Philippines Net. Philhealth coverage for hemodialysis. 2017. Available at: <http://www.healthphilippines.net/2014/08/philhealth-coverage-for-hemodialysis/> [Accessed 01/07/2022].
57. PhilHealth Circular. PD First Z Benefits: The Z Benefits for End-Stage Renal Disease Requiring Peritoneal Dialysis (Revision 1). 2016. Available at: [https://www.philhealth.gov.ph/circulars/2016/TS\\_circ2016-021.pdf](https://www.philhealth.gov.ph/circulars/2016/TS_circ2016-021.pdf) [Accessed 03/01/2023].
58. National Kidney and Transplant Institute. Frequently asked questions: How much does a kidney transplant cost? 2020. Available at: <https://nkti.gov.ph/index.php/patients-and-visitors/frequently-asked-questions#how-much-do-kidney-transplant-cost> [Accessed 01/07/2022].
59. Agoot L. Baguio hospital gets DOH nod as kidney transplant center. 2022. Available at: <https://www.pna.gov.ph/articles/1173155> [Accessed 01/01/2023].
60. Hałdaś M, Chudzicka A, Ziobro M, et al. Reaching Therapeutic Goals Impacts on Estimated Cost of Illness for Patients with Type 2 Diabetes in Poland. *Journal of Health Policy & Outcomes Research*. 2015;1:44-55.
61. Digital N. Healthcare costing standards for England. Acute: Costing methods. 2019. Available at: [https://www.england.nhs.uk/wp-content/uploads/2020/08/Acute\\_CMs\\_standards20.pdf](https://www.england.nhs.uk/wp-content/uploads/2020/08/Acute_CMs_standards20.pdf) [Accessed 01/07/2022].
62. Ministerio de Sanidad. Hospital discharge records in the national health system. 2021.
63. Arrieta J, Rodríguez-Carmona A, Remón C, et al. Peritoneal dialysis is the best cost-effective alternative for maintaining dialysis treatment. *Nefrología*. 2011;31(5):505-13.

64. von Zur-Mühlen B, Wintzell V, Levine A, et al. Healthcare Resource Use, Cost, and Sick Leave Following Kidney Transplantation in Sweden: A Population-Based, 5-Year, Retrospective Study of Outcomes: COIN. *Ann Transplant*. 2018;23(852-866).
65. Kao TW, Chang YY, Chen PC, et al. Lifetime costs for peritoneal dialysis and hemodialysis in patients in Taiwan. *Perit Dial Int*. 2013;33(6):671-8.
66. Tang CH, Wu YT, Huang SY, et al. Economic costs of automated and continuous ambulatory peritoneal dialysis in Taiwan: a combined survey and retrospective cohort analysis. *BMJ Open*. 2017;7(3):e015067.
67. Chen HY, Kuo S, Su PF, et al. Health Care Costs Associated With Macrovascular, Microvascular, and Metabolic Complications of Type 2 Diabetes Across Time: Estimates From a Population-Based Cohort of More Than 0.8 Million Individuals With Up to 15 Years of Follow-up. *Diabetes Care*. 2020;43(8):1732-40.
68. Thaweethamcharoen T, Sakulbumrungsil R, Nopmaneejumruslers C, et al. Cost-Utility Analysis of Erythropoietin for Anemia Treatment in Thai End-Stage Renal Disease Patients with Hemodialysis. *Value Health Reg Issues*. 2014;3:44-9.
69. Kanjanabuch TA-O, Takkavatakarn K. Global Dialysis Perspective: Thailand. *Kidney360*. 2020;1(7):671-5.
70. Permsuwan U, Dilokthornsakul P, Saokaew S, et al. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand. *Clinicoecon Outcomes Res*. 2016;8:521-9.
71. Turkish health benefit schedule.
72. NHS Improvement. Healthcare costing standards for England - Acute: Costing methods. 2019. Available at: [https://www.england.nhs.uk/wp-content/uploads/2020/08/Acute\\_CM\\_s\\_standards20.pdf](https://www.england.nhs.uk/wp-content/uploads/2020/08/Acute_CM_s_standards20.pdf) [Accessed 01/07/2022].
73. NHS Improvement. National Schedule of NHS Costs 2018/19. 2021. Available at: <https://www.england.nhs.uk/publication/2018-19-national-cost-collection-data-publication/> [Accessed 01/07/2022].
74. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. *Am J Kidney Dis*. 2020;75(1 Suppl 1):A6-A7.
75. Elbasha E, Greaves W, Roth D, et al. Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States. *J Viral Hepat*. 2017;24(4):268-79.
76. Axelrod DA, Schnitzler MA, Xiao H, et al. An economic assessment of contemporary kidney transplant practice. *Am J Transplant*. 2018;18(5):1168-76.
77. Ioannides-Demos LL, Makarounas-Kirchmann K, Ashton E, et al. Cost of myocardial infarction to the Australian community: a prospective, multicentre survey. *Clin Drug Investig*. 2010;30(8):533-43.
78. Scuffham PA, Ball J, Horowitz JD, et al. Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial. *Eur Heart J*. 2017;38(30):2340-8.
79. Deloitte Access Economics. Economic impact of stroke in Australia. 2020. Available at: <https://www2.deloitte.com/content/dam/Deloitte/au/Documents/Economics/deloitte-au-dae-economic-impact-stroke-report-061120.pdf> [Accessed 01/07/2022].
80. Independent Hospital Pricing Authority. National Efficient Price Determination 2022–23. 2022.
81. Stevens B, Pezzullo L, Verdian L, et al. The economic burden of hypertension, heart failure, myocardial infarction, and atrial fibrillation in Mexico. *Arch Cardiol Mex*. 2018;88(3):241-4.
82. Oliveira GMM, Brant LCC, Polanczyk CA, et al. Cardiovascular Statistics - Brazil 2020. *Arq Bras Cardiol*. 2020;115(3):308-439.

83. Souza Júnior E, Pires D, Nunes G, et al. Acute kidney failure in Northeast Brazil: morbimortality and public costs. 2019;13.
84. Tran DT, Ohinmaa A, Thanh NX, et al. The Healthcare Cost Burden of Acute Myocardial Infarction in Alberta, Canada. *Pharmacoecon Open*. 2018;2(4):433-42.
85. Zaour N, Barbeau M, Liu N, et al. THE COST OF HOSPITALIZATION AND LENGTH OF STAY FOR CHRONIC HEART FAILURE CASES IN CANADA. *Canadian Journal of Cardiology*. 2015;31:S273.
86. Krueger H, Lindsay P, Cote R, et al. Cost avoidance associated with optimal stroke care in Canada. *Stroke*. 2012;43(8):2198-206.
87. Collister D, Pannu N, Ye F, et al. Health Care Costs Associated with AKI. *Clin J Am Soc Nephrol*. 2017;12(11):1733-43.
88. Liu YM, Ma J, Li C, et al. Analysis of hospitalization medical expenses and influencing factors of patients with myocardial infarction. *Chinese Public Health*. 2013(3):322-4.
89. Huang J, Yin H, Zhang M, et al. Understanding the economic burden of heart failure in China: impact on disease management and resource utilization. *J Med Econ*. 2017;20(5):549-53.
90. Zhu DA-O, Shi XA-O, Nicholas S, et al. Medical Service Utilization and Direct Medical Cost of Stroke in Urban China. *Int J Health Policy Manag*. 2022;11(3):277-86.
91. Yang L, Xing G, Wang L, et al. Acute kidney injury in China: a cross-sectional survey. *Lancet*. 2015;386(10002):1465-71.
92. Baeza-Cruz G, Peniche-Otero G, Alva-Esqueda ME, et al. Análisis de Costo de la Enfermedad, del Tratamiento, las Complicaciones e Intervenciones de la Hipercolesterolemia en México en 2016. *Value Health Reg Issues*. 2018;17:56-63.
93. Sistema Integrado de Información de la Protección Social.
94. Schmid T. Costs of treating cardiovascular events in Germany: a systematic literature review. *Health Econ Rev*. 2015;5(1):27.
95. Bundgaard JS, Mogensen UM, Christensen S, et al. The economic burden of heart failure in Denmark from 1998 to 2016. *Eur J Heart Fail*. 2019;21(12):1526-31.
96. Jennum P, Iversen HK, Ibsen R, et al. Cost of stroke: a controlled national study evaluating societal effects on patients and their partners. *BMC Health Serv Res*. 2015;15:466.
97. Kim K, Thomsen RA-O, Nicolaisen SK, et al. Healthcare resource utilisation and cost associated with elevated potassium levels: a Danish population-based cohort study. *BMJ Open*. 2019;9(4):e026465.
98. Sundhedsdatastyrelsen. DRG-takster. 2018. Available at: <https://sundhedsdatastyrelsen.dk/da/afregning-og-finansiering/takster-drg/takster-2018> [Accessed 01/07/2022].
99. Emery C, Torretón E, Briere JB, et al. Economic burden of coronary artery disease or peripheral artery disease in patients at high risk of ischemic events in the French setting: a claims database analysis. *J Med Econ*. 2020;23(5):513-20.
100. Caisse nationale de l'assurance maladie (CNAM). Améliorer la qualité du système de santé et maîtriser les dépenses. Propositions de l'Assurance maladie pour 2020. 2019. Available at: <https://assurance-maladie.ameli.fr/sites/default/files/rapport-charges-et-produits-2020.pdf> [Accessed 01/07/2022].
101. Chevreur K, Durand-Zaleski I, Gouépo A, et al. Cost of stroke in France. *Eur J Neurol*. 2013;20(7):1094-100.
102. Aubry P, Brillet G, Catella L, et al. Outcomes, risk factors and health burden of contrast-induced acute kidney injury: an observational study of one million hospitalizations with image-guided cardiovascular procedures. *BMC Nephrology*. 2016;17(1):167.
103. NHS Reference Costs.
104. Maniadakis N, Kourlaba G, Cokkinos DV, et al. The economic burden of atherothrombosis in Greece: results from the THESIS study. *Eur J Health Econ*. 2013;14(4):655-65.
105. Stafylas P, Farmakis D, Kourlaba G, et al. The heart failure pandemic: The clinical and economic burden in Greece. *Int J Cardiol*. 2017;227:923-9.

106. Ministry of Health. KEN-DRG Payment.
107. Lorenzovici L, Székely A, Csanádi M, et al. Cost Assessment of Inpatient Care Episodes of Stroke in Romania. *Front Public Health*. 2020;8:605919.
108. Polish NHF Data. Codes 415, L82 Ostra niewydolność nerek [Acute renal failure].
109. Singh A, Chauhan S, Devasia T, et al. Financial burden of heart failure in a developing country: cost analysis from Manipal Heart Failure Registry, India. *Journal of Public Health*. 2021;29(3):585-94.
110. Kwatra G, Kaur P, Toor G, et al. Cost of stroke from a tertiary center in northwest India. *Neurol India*. 2013;61(6):627-32.
111. Silver SA, Long J, Zheng Y, et al. Cost of Acute Kidney Injury in Hospitalized Patients. *Journal of Hospital Medicine*. 2017;12(2):70-6.
112. Ministry of Health. Price list for ambulatory services and hospitalization services. 2022. Available at: <https://www.gov.il/he/Departments/DynamicCollectors/moh-price-list?skip=0> [Accessed 01/07/2022].
113. Taylor MJ, Scuffham PA, McCollam PL, et al. Acute coronary syndromes in Europe: 1-year costs and outcomes. *Curr Med Res Opin*. 2007;23(3):495-503.
114. Maggioni AP, Orso F, Calabria S, et al. The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database. *Eur J Heart Fail*. 2016;18(4):402-10.
115. Fattore G, Torbica A, Susi A, et al. The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness study. *BMC Neurol*. 2012;14(12):137.
116. Ministeria della Salute. Direzione generale della programmazione sanitaria - Ufficio 6: Rapporto annuale sull'attività di ricovero ospedaliero. 2022. Available at: [https://www.salute.gov.it/imgs/C\\_17\\_pubblicazioni\\_3277\\_allegato.pdf](https://www.salute.gov.it/imgs/C_17_pubblicazioni_3277_allegato.pdf) [Accessed July 2022].
117. Kamae I, Hashimoto Y, Koretsune Y, et al. Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan. *Clin Ther*. 2015;37(12):2837-51.
118. Mizuno A, Iguchi H, Sawada Y, et al. The impact of carperitide usage on the cost of hospitalization and outcome in patients with acute heart failure: High value care vs. low value care campaign in Japan. *Int J Cardiol*. 2017;241:243-8.
119. Yamamoto H, Yoshikawa M, M. Y, et al. Comparative study of CHDF and IHD in patients with acute renal failure. *ICU and CCU*. 2005;29:S251-S2.
120. Diario Oficial de la Federacion. Aprobación de los Costos Unitarios por Nivel de Atención Médica actualizados al año 2022. 2022. Available at: [Accessed 01/07/2022].
121. Luengo-Fernandez R, Violato M, Candio P, et al. Economic burden of stroke across Europe: A population-based cost analysis. *Eur Stroke J*. 2020;5(1):17-25.
122. Danese MD, Gleeson M, Kutikova L, et al. Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. *Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK*. 2016;6(8):e011805.
123. Stewart S, Carrington MJ, Marwick TH, et al. Impact of home versus clinic-based management of chronic heart failure: the WHICH? (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care) multicenter, randomized trial. *J Am Coll Cardiol*. 2012;60(14):1239-48.
124. Erasmus MC. List of passers-by prices. Available at: <https://www.erasmusmc.nl/en/patient-care/list-prices> [Accessed 01/07/2022].
125. Azmi S, et al.,. PCV34 Cost and Treatment Duration for Acute Myocardial Infarction in South East Asia. *Value in Health*. 2012;15(4).
126. Navarro JC, Baroque ACn, Lokin JK, et al. The real stroke burden in the Philippines. *Int J Stroke*. 2014;9(5):640- 1.

127. Philippine Health Insurance Corporation. Philhealth case rate search. 2022. Available at: <https://crs.philhealth.gov.ph/> [Accessed 01/02/2023].
128. Lorenzovici L, Bârzan-Székely A, Farkas-Ráduly S, et al. Burden of Chronic Heart Failure in Romania. *Healthcare (Basel)*. 2022;10(1):107.
129. Farré NA-O, Vela E, Clèries M, et al. Real world heart failure epidemiology and outcome: A population-based analysis of 88,195 patients. *PLoS One*. 2017;12(2):e0172745.
130. Alvarez-Sabín J, Quintana M, Masjuan J, et al. Economic impact of patients admitted to stroke units in Spain. *Eur J Health Econ*. 2017;18(449-458).
131. Almalki ZS, Iqbal MS, Alablan FM, et al. Long Term Cost-Effectiveness of a Systolic Blood Pressure Goal of <120 mmHg in Hypertensive Patients Without Diabetes Mellitus. *Value Health Reg Issues*. 2020;21:157-63.
132. Turchetti G, Bellelli S, Amato M, et al. The social cost of chronic kidney disease in Italy. *Eur J Health Econ*. 2016;18(7):847-58.
133. Ng CA-O, Toh MP, Ng J, et al. Direct medical cost of stroke in Singapore. *Int J Stroke*. 2015;10(A100):75-82.
134. Health Insurance Review & Assessment Service. Healthcare bigdata hub. 2015. Available at: <https://opendata.hira.or.kr/home.do> [Accessed 01/07/2022].
135. Seo H, Yoon SJ, Yoon J, et al. Recent trends in economic burden of acute myocardial infarction in South Korea. *PLoS One*. 2015;10(2):e0117446.
136. Lee H, Oh SH, Cho H, et al. Prevalence and socio-economic burden of heart failure in an aging society of South Korea. *BMC Cardiovasc Disord*. 2016;16(1):215.
137. Cha YJ. The Economic Burden of Stroke Based on South Korea's National Health Insurance Claims Database. *International Journal of Health Policy and Management*. 2018;7(10):904-9.
138. Escobar C, Morales C, Capel M, et al. Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study. *Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study*. 2022;22(1):217.
139. Ministerio de Sanidad Consumo y Bienestar Social. Conjunto Mínimo Básico de Datos (CMBD). Registro de Atención Especializada. 2021. Available at: <http://pestadistico.inteligenciadegestion.mssi.es/> [Accessed 01/07/2022].
140. Hallberg SA-O, Gandra SR, Fox KM, et al. Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data. *Eur J Health Econ*. 2016;17(5):591-601.
141. Sveriges Kommuner och Regioner. Kostnad per patient, KPP. 2022. Available at: <https://skr.se/skr/halsasjukvard/ekonomiavgifter/kostnadperpatientkpp.1076.html> [Accessed 01/11/2022].
142. Ministry of Health and Welfare. Statistics of chronic diseases in the population over 18 years of age (stratified by diseases). 2013. Available at: <https://dep.mohw.gov.tw/dos/cp-1720-7333-113.html> [Accessed 01/05/2022].
143. Ministry of Health and Welfare. National Health Insurance Medical Statistics.
144. Thai CaseMix Centre. Thai DRGs Version 6.2. 2022. Available at: <https://ww2.chi.or.th/dataupload/DRG/Ref/2560/TDRGVersion6.2V/TDRGVersion6.2V1.pdf> [Accessed 01/08/2022].
145. Aras D, Aydoğdu S, Bozkurt E, et al. Cost of heart failure management in Turkey: results of a Delphi Panel. *Balkan Med J*. 2016;39(4):282-9.
146. Chirikov VV, Walker C, Stephens JM, et al. Evaluating the Cost-Effectiveness of Celecoxib versus Ibuprofen and Naproxen in Patients with Osteoarthritis in United Arab Emirates Based on the PRECISION Trial. *Clinicoecon Outcomes Res*. 2021;13:409-20.
147. Stewart S, Jenkins A, Buchan S, et al. The current cost of heart failure to the National Health Service in the UK. *Eur J Heart Fail*. 2002;4(3):361-71.

148. Kerr M. Chronic kidney disease in England: the human and financial cost. NHS Kidney Care. 2012. Available at: <https://www.england.nhs.uk/improvement-hub/wp-content/uploads/sites/44/2017/11/Chronic-Kidney-Disease-in-England-The-Human-and-Financial-Cost.pdf> [Accessed 01/07/2022].
149. Erickson KF, Japa S, Owens DK, et al. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. *J Am Coll Cardiol*. 2013;61(12):1250-8.
150. Zeng X, McMahon GM, Brunelli SM, et al. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. *Clin J Am Soc Nephrol*. 2013;9(1):12-20.